Ganomycin I from Ganoderma lucidum attenuates RANKL-mediated osteoclastogenesis by inhibiting MAPKs and NFATc1
ConclusionOur findings suggest that GMI can attenuate osteoclast formation by suppressing RANKL-mediated MAPKs and NFATc1 signaling pathways and the anti-osteoclastogenic activity of GMI may extend our understanding of molecular mechanisms underlying biological activities and pharmacological use of G. lucidum as a traditional anti-osteoporotic medicine.Graphical Abstract
Source: Phytomedicine - Category: Drugs & Pharmacology Source Type: research
More News: Arthritis | Drugs & Pharmacology | Ganoderma | Genetics | Molecular Biology | Mushrooms | Orthopaedics | Osteoporosis | Rheumatoid Arthritis | Rheumatology | Study | Vietnam Health